Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript

SA Transcripts 162.12K Followers Follow Roivant Sciences Ltd. ( ROIV ) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD September 8, 2026 8:00 AM EDT Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants Yaron Werber - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Yuchen Ding - Jefferies LLC, Research Division Chi Meng Fong - BofA Securities, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Mosliciguat in PH-ILD PHocus Study Top Line Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Stephanie Lee, please go ahead. Stephanie Lee Griffin Chief Operating Officer of Roivant Platforms Good morning, and thanks for joining today's call to review the results from the PHocus study of Mosliciguat in PH-ILD. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we will be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt.